D-0302-2019 Class II Terminated
FDA drug recall D-0302-2019 was initiated by Westminster Pharmaceuticals Llc on Oct 29, 2018 and is designated Class II. Reason for recall: CGMP Deviations: FDA laboratory testing confirmed traces of NDEA impurity in specific lots of Irbesartan. The recall status is terminated (terminated Oct 26, 2021). Affected quantity: 3976 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Dec 19, 2018
- Initiation Date
- Oct 29, 2018
- Termination Date
- Oct 26, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 3976 bottles
Product description
Westminster Irbesartan Tablets, USP 300 mg Rx Only Manufactured by: ScieGen Pharmaceuticals, Inc. Hauppauge, NY 11788 Manufactured for: Westminster Pharmaceuticals, LLC. Olive Branch, MS 38654 a) 30 count bottle NDC 69367-121-01; b) 90 count bottle NDC 69367-121-03
Reason for recall
CGMP Deviations: FDA laboratory testing confirmed traces of NDEA impurity in specific lots of Irbesartan.
Distribution pattern
Nationwide.
Code information
Batch Numbers: a) B162008A Exp. 09/30/2019, C162002A Exp. 02/29/2020; b) B162008B Exp. 09/30/2019, C162002B Exp. 02/29/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0302-2019
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026